📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 17:52
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
12 announcements match the current filters (relevance ≥ 5).
Vital Chemtech Appoints Jitendra Raval as CFO; Reports ₹11,800 Exchange Fine for Minor Delay
Vital Chemtech Limited announced the appointment of Mr. Jitendra Raval as Chief Financial Officer with effect from August 15, 2026, succeeding Mr. Vipul Bhatt, who stepped down as CFO to focus on his role as Chairman and Managing Director. Mr. Raval brings 25 years of finance experience, including 15 years in the chemical industry with firms like Meghmani Group. Additionally, the Board reviewed and recorded a minor fine of ₹11,800 levied by NSE for a one-day technical delay in intimating a prior board meeting due to an exchange holiday.
Confidence: HIGH
What changedSeparation of the CFO role from the Chairman & MD, with veteran finance professional Jitendra Raval taking over as CFO.
Why it mattersStrengthens corporate governance and compliance bandwidth following the company's recent migration from the SME platform to the Main Board.
Exchange fine levied: ₹11,800CFO experience in chemical industry: 15 yearsCFO total professional experience: 25 yearsEffective date of CFO appointment: August 15, 2026
📅 Short termAdministrative transition with negligible financial impact from the ₹11,800 exchange penalty.
📈 Long termProfessionalizing the leadership team improves financial reporting and internal controls as the company scales on the Main Board.
⚠ Risk flags
- Compliance oversight risk highlighted by the minor exchange intimation delay
Key Highlights
Appointed Mr. Jitendra Raval as CFO effective August 15, 2026, bringing 25 years of overall finance experience
Mr. Vipul Bhatt resigned as CFO effective August 14, 2026, while continuing as Chairman and Managing Director
NSE imposed a fine of ₹11,800 (inclusive of GST) under Regulation 29(2) for a 1-day intimation delay attributed to an exchange holiday
Company completed migration from NSE Emerge to the NSE Main Board effective March 11, 2026
👀 What to Watch
Track the execution of financial controls, ERP systems, and reporting under the new CFO as the company operates under Main Board compliance standards.
Vital Chemtech Appoints Jitendra Raval as CFO; CMD Vipul Bhatt Steps Down from CFO Role
Vital Chemtech has separated its executive leadership functions as Chairman and Managing Director Vipul Bhatt stepped down from the additional role of Chief Financial Officer effective August 14, 2026. The company appointed Mr. Jitendra Raval as the new CFO effective August 15, 2026, who brings 25 years of finance experience including 15 years in the chemical sector. Alongside the leadership transition, the Board approved Q1 FY27 results reporting consolidated basic EPS of Rs 1.08 (vs Rs 0.36 in Q4 FY26). The Board also acknowledged a minor procedural fine of Rs 11,800 levied by NSE for a one-day delay in meeting intimation.
Confidence: HIGH
What changedSeparation of CMD and CFO roles with the appointment of external professional Jitendra Raval as the new CFO.
Why it mattersEnhances corporate governance and financial oversight as the company adapts to the stricter compliance and reporting demands of the Main Board.
New CFO Effective Date: August 15, 2026New CFO Chemical Industry Experience: 15 yearsConsolidated Q1 EPS: Rs 1.08Stock Exchange Fine: Rs 11,800
📅 Short termOrderly transition expected without disruption to daily operations as CMD Vipul Bhatt remains at the helm of the company.
📈 Long termStrengthens financial management and internal controls needed for scaling specialized chemical and alkoxide manufacturing.
Key Highlights
Vipul Bhatt resigned as CFO effective August 14, 2026, while continuing as Chairman & Managing Director.
Jitendra Raval appointed as Chief Financial Officer effective August 15, 2026, with 25 years of overall finance experience and 15 years in the chemical sector.
Consolidated Basic EPS for the quarter ended June 30, 2026 stood at Rs 1.08 per share compared to Rs 0.36 in the prior quarter.
NSE imposed a fine of Rs 11,800 (inclusive of GST) regarding a technical 1-day delay in board meeting intimation caused by an exchange holiday.
👀 What to Watch
Monitor upcoming quarterly disclosures and working capital management under the newly appointed CFO following the company's transition to the Main Board.
Vital Chemtech Appoints Jitendra Raval as CFO, Separating Role from CMD
Vital Chemtech Limited has appointed Mr. Jitendra Raval as Chief Financial Officer effective August 15, 2026. Mr. Vipul Bhatt has resigned as CFO effective August 14, 2026, to facilitate the transition to professional management, while continuing as Chairman and Managing Director. Mr. Raval brings 25 years of overall finance experience, including 15 years in the chemical manufacturing industry. Additionally, the Board noted a minor technical fine of ₹11,800 imposed by the NSE for a 1-day delay in board meeting intimation.
Confidence: HIGH
What changedMr. Jitendra Raval has taken over as full-time CFO, relieving Chairman & Managing Director Vipul Bhatt of dual CFO responsibilities.
Why it mattersSeparating the CMD and CFO roles and bringing in a chemical-sector finance veteran improves corporate governance and compliance execution as the company scales on the Main Board.
New CFO Total Experience: 25 yearsNew CFO Chemical Sector Experience: 15 yearsNSE Compliance Fine: ₹11,800Q1 Basic EPS: ₹1.08
📅 Short termAdministrative transition with minimal immediate operational or financial impact.
📈 Long termEnhances internal financial controls, reporting rigor, and governance structure as the firm navigates Main Board compliance standards.
⚠ Risk flags
- Past compliance lapses (minor exchange intimation delay)
Key Highlights
Appointed Chartered Accountant Jitendra Raval as CFO effective August 15, 2026.
Mr. Raval brings 25 years of experience in finance and accounts, with 15 years in the chemical sector.
Promoter Vipul Bhatt stepped down from the CFO role to separate executive duties but continues as CMD.
Board recorded payment of ₹11,800 fine levied by NSE due to an inadvertent 1-day delay in meeting intimation.
Reported basic/diluted EPS of ₹1.08 for the quarter ended June 30, 2026.
👀 What to Watch
Track subsequent quarterly financial reporting and disclosures under the new CFO following the company's Main Board migration.
Vital Chemtech Appoints Jitendra Raval as CFO; CMD Vipul Bhatt Steps Down as CFO
Vital Chemtech announced the appointment of Jitendra Raval as Chief Financial Officer effective August 15, 2026, bringing 25 years of finance experience, including 15 years in the chemical industry. Vipul Bhatt stepped down from the CFO role to separate executive functions while continuing as Chairman and Managing Director. The Board also approved unaudited Q1 FY27 results (reporting consolidated Basic EPS of ₹1.08) and addressed a nominal ₹11,800 fine levied by NSE for a technical one-day board meeting intimation delay.
Confidence: HIGH
What changedVipul Bhatt stepped down as CFO while continuing as CMD; Jitendra Raval took over as the dedicated professional Chief Financial Officer.
Why it mattersSeparation of the CMD and CFO positions strengthens corporate governance and financial controls as the company scales operations on the Main Board.
New CFO Total Experience: 25 yearsNew CFO Chemical Industry Experience: 15 yearsConsolidated Q1 Basic EPS: ₹1.08NSE Fine Amount: ₹11,800
📅 Short termPositive for institutional sentiment due to enhanced governance standards and professionalization of key management personnel.
📈 Long termProfessional financial stewardship should assist in navigating Ind AS compliance, scaling alkoxide manufacturing, and capital allocation.
⚠ Risk flags
- Adherence to stricter Main Board regulatory and reporting timelines
Key Highlights
Appointed Chartered Accountant Jitendra Raval as CFO effective August 15, 2026, with 25 years of financial management experience
CMD Vipul Bhatt relinquished the CFO post on August 14, 2026, separating management and finance responsibilities
Reported consolidated Basic EPS of ₹1.08 for the quarter ended June 30, 2026
Board addressed and noted payment of ₹11,800 technical penalty imposed by NSE for a 1-day delay in meeting intimation
👀 What to Watch
Track subsequent quarterly financial reports and working capital management under the newly appointed CFO following the company's migration to the Main Board.
Vital Chemtech Subsidiary Receives GPCB Consent Order Valid Until March 2031
Vital Chemtech's subsidiary, Vital Synthesis Limited, has secured a final Consolidated Consent and Authorization (CCA) from the Gujarat Pollution Control Board (GPCB). This regulatory milestone provides long-term operational visibility as the approval is valid until March 26, 2031. The consent allows the subsidiary to proceed with manufacturing advanced intermediates and custom synthesis, effectively reducing compliance risks and supporting the group's overall expansion strategy in the specialty chemicals market.
Key Highlights
Subsidiary Vital Synthesis Limited received final CCA approval from Gujarat Pollution Control Board.
The regulatory approval is valid for a long-term period ending March 26, 2031.
Enables manufacturing operations for advanced intermediates and custom synthesis projects.
Strengthens the company's ESG and governance profile by ensuring environmental compliance.
Provides multi-year operational visibility for the subsidiary's growth and expansion plans.
👀 What to Watch
Investors should monitor the production ramp-up at Vital Synthesis Limited now that regulatory hurdles are cleared. This approval de-risks the subsidiary's operations and supports long-term revenue growth potential.
Vital Chemtech Subsidiary Receives GPCB Consent Order Valid Until March 2031
Vital Chemtech's subsidiary, Vital Synthesis Limited, has received the Final Consent Order (CC&A) from the Gujarat Pollution Control Board (GPCB). This regulatory approval allows the subsidiary to manufacture products under the Water, Air, and Environment Protection Acts. The authorization is valid for a long-term period until March 26, 2031, ensuring operational stability and legal compliance for the subsidiary's manufacturing activities.
Key Highlights
Subsidiary Vital Synthesis Limited received Consolidated Consent and Authorization (CC&A) via CCA No. AWH-157796.
The regulatory approval from GPCB is valid for nearly five years, expiring on March 26, 2031.
The consent covers compliance under the Water Act-1974, Air Act-1981, and Hazardous Waste Rules-2016.
This clearance is a critical milestone for the subsidiary to commence or continue manufacturing operations legally.
👀 What to Watch
Investors should view this as a positive development that clears regulatory hurdles for the subsidiary's production. Monitor for updates regarding the commencement of commercial production or revenue contributions from this unit.
Vital Chemtech Subsidiary Receives GPCB Manufacturing Consent Valid Until March 2031
Vital Chemtech Limited's subsidiary, Vital Synthesis Limited, has secured a Provisional Consent Order (CC&A) from the Gujarat Pollution Control Board (GPCB). This authorization allows the manufacturing of products under the Water, Air, and Environment Protection Acts. The license is valid for a five-year period, expiring on March 26, 2031. This regulatory milestone ensures legal compliance and operational continuity for the subsidiary's manufacturing activities.
Key Highlights
Subsidiary Vital Synthesis Limited received Consolidated Consent and Authorization (CC&A) from GPCB.
The regulatory approval is valid for a period of 5 years, ending on March 26, 2031.
The consent covers compliance under the Water Act (1974), Air Act (1981), and Environment Protection Act (1986).
The application for this fresh CCA was originally filed on March 27, 2026, and received on June 4, 2026.
👀 What to Watch
Investors should view this as a positive development as it secures the necessary legal framework for the subsidiary's operations. Monitor for future updates regarding production capacity and revenue contributions from this unit.
Vital Chemtech FY26 PAT Drops 74% to ₹1 Cr Amid Subsidiary Investments; Q4 EBITDA Up 40%
Vital Chemtech reported a challenging FY26 with a 5.6% decline in annual revenue to ₹126.4 crore and a sharp 74.1% drop in PAT to ₹1.0 crore. The bottom line was significantly impacted by heavy investments in its subsidiaries, Vital Synthesis and Vital Alkoxides, which are intended to drive long-term growth in specialty chemicals. However, Q4 FY26 showed operational resilience with EBITDA growing 39.7% YoY to ₹4.0 crore and margins expanding to 11.3%. While annual profitability is under pressure, the subsidiary Vital Alkoxides showed strong momentum with 63% revenue growth.
Key Highlights
FY26 Revenue declined 5.6% YoY to ₹126.4 crore, while annual PAT plummeted 74.1% to ₹1.0 crore.
Q4 FY26 EBITDA grew by 39.7% YoY to ₹4.0 crore with margins improving by 320 bps to 11.3%.
Subsidiary Vital Alkoxides delivered strong performance with approximately 63% YoY revenue growth in FY26.
Vital Synthesis commenced commercial operations in Q3 FY26, marking a key milestone for the specialty chemicals portfolio.
Full-year PAT margin contracted significantly from 3.0% in FY25 to 0.8% in FY26 due to subsidiary-related investment costs.
👀 What to Watch
Investors should monitor the scale-up of the new subsidiary, Vital Synthesis, and the continued growth of Vital Alkoxides to see if they can restore overall profitability. The stock is currently in a 'watch' phase as the company navigates an investment-heavy period for long-term capacity building.
Vital Chemtech Approves Audited FY26 Results; Receives Clean Audit Report
Vital Chemtech Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The statutory auditors, M/s. Abhishek Kumar & Associates, issued an unmodified opinion, indicating that the financial statements present a true and fair view of the company's affairs. Additionally, the board has appointed M/s R J & Associates as the Cost Auditor for the upcoming 2026-27 fiscal year to ensure regulatory compliance and cost efficiency.
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Statutory auditors issued an unmodified audit opinion, confirming no major accounting discrepancies.
Appointed M/s R J & Associates as Cost Auditors for the financial year 2026-27.
Submitted the full statement of assets, liabilities, and cash flows for the period ending March 31, 2026.
👀 What to Watch
Investors should review the detailed profit and loss figures in the full financial report to assess year-on-year growth. The unmodified audit opinion is a positive sign of financial transparency and corporate governance.
Vital Chemtech Approves FY26 Audited Results; Appoints R J & Associates as Cost Auditor
Vital Chemtech Limited has approved its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The company's statutory auditors, Abhishek Kumar & Associates, issued an unmodified opinion, indicating that the financial statements are presented fairly in all material respects. Additionally, the board has appointed M/s R J & Associates as the Cost Auditor for the 2026-27 financial year. This announcement confirms the completion of the annual audit process and ensures regulatory compliance for the upcoming year.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an unmodified opinion on the financial results, confirming accounting integrity.
Appointed M/s R J & Associates, Cost Accountants, as Cost Auditor for the Financial Year 2026-27.
The board meeting concluded on May 29, 2026, after a two-hour session starting at 06:30 PM IST.
👀 What to Watch
Investors should examine the detailed profit and loss statements and balance sheets for FY26 to assess the company's operational efficiency. The unmodified audit report is a positive indicator of the company's financial reporting standards.
Vital Chemtech Approves FY26 Audited Results with Unmodified Audit Opinion
Vital Chemtech Limited's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, during their meeting on May 29, 2026. The statutory auditors, M/s. Abhishek Kumar & Associates, issued an unmodified opinion, confirming the accuracy and fairness of the financial statements. Additionally, the company has appointed M/s R J & Associates as the Cost Auditor for the financial year 2026-27. This announcement confirms the completion of the annual audit process with no reported discrepancies.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, indicating a clean audit report for the company.
Appointed M/s R J & Associates, Cost Accountants, as Cost Auditors for the financial year 2026-27.
The Board meeting concluded at 08:30 PM IST following a two-hour session.
👀 What to Watch
Investors should examine the detailed profit and loss statements and balance sheets once the full tables are released to assess year-on-year growth. The unmodified audit opinion is a positive sign of corporate governance and financial transparency.
Vital Chemtech Migrates to NSE Main Board Effective March 11, 2026
Vital Chemtech Limited has received final approval from the National Stock Exchange (NSE) to migrate its equity shares from the SME Emerge platform to the Main Board. Trading on the Main Board will commence on March 11, 2026, involving 2,39,51,100 equity shares with a face value of Rs. 10 each. This transition is a significant milestone that typically enhances stock liquidity and visibility. The migration follows the company's initial listing on the SME platform in November 2022.
Key Highlights
Migration from NSE SME Emerge platform to the NSE Main Board effective March 11, 2026
Total of 2,39,51,100 equity shares of face value Rs. 10 each to be admitted for trading
Market lot size reduced to 1 share from previous SME lot requirements, improving retail accessibility
Final approval received via NSE circular Ref. No. NSE/CML/73204 dated March 09, 2026
👀 What to Watch
Investors should monitor the stock for increased liquidity and potential institutional interest following the migration. The removal of SME lot size restrictions makes the stock more accessible for retail portfolios.
